logo
Ministers urged to provide more graduate training slots for UK medical students

Ministers urged to provide more graduate training slots for UK medical students

Dr Peter Prinsley, a retired ENT (ear, nose and throat) specialist who was elected for Labour last year, said thousands of British medicine graduates were missing out on doing further training every year because of a lack of places combined with the pressures from international medical graduates in the NHS.
The British Medical Association has said about 20,000 applicants will miss out this year, if the number of available posts are the same. It added that according to the latest figures, there were 4.7 applications per post.
The MP for Bury St Edmunds and Stowmarket said it had led to graduates moving abroad to do further study who sometimes do not return. He added there should be reserved spaces for UK graduates to be able to specialise and do further study.
33,108
Medical graduates applying for training posts British Medical Association
Dr Prinsley told the PA news agency: 'The problem is that we've got a distorted competition ratio for the professional training slots.
'It should be a reasonable expectation that if you graduate from the UK medical school, you should have a reasonable chance of getting into higher professional training.
'There should be some competition. It shouldn't just be that you automatically progress with no effort, there should be a bit of competition, but the competition ratios have been hugely distorted by the requirement of the hospitals to provide junior doctors to staff their rotas.'
It comes as Wes Streeting said UK medical graduates will be given priority for NHS jobs under the upcoming 10-year health plan.
The Health Secretary told medical website doctors.net.uk on Thursday: 'I want to make sure that if you go through your medical training here in the UK, that you're able to work in the UK.'
Mr Streeting added it was 'completely bonkers' to invest in training doctors but not ensure they can stay in the UK to work.
The latest figures from the BMA showed there were 33,108 medical graduates applying for around 13,000 posts. This includes 12,305 UK graduates and 20,803 from overseas.
The number of international medical graduates has doubled in two years, the figures show, while the UK ones have only risen by a third.
The sharp rise in the number of international medical graduates has been down to the increased demand for doctors in the NHS to fill hospital vacancies.
In 2023 more than two-thirds of new doctors (68%) joining the NHS were non-UK graduates, up from 47% in 2017.
In a statement, the Department for Health and Social Care said the Government should not be 'over-reliant' on overseas recruitment.
The problem has two solutions. We need less international medical graduates being recruited by the hospitals. We need to find an alternative way of staffing the rotas to run the hospitals Dr Peter Prinsley
Doctors can go on to do further training after two foundation years in the NHS.
If they apply and miss out on further study, they then move on to so-called foundation three status, where they can work as locums and apply for jobs within individual trusts. Some, however, opt to move abroad to work or study.
The number doing another foundation year has risen in recent years. In its latest workforce report, the General Medical Council said the number of doctors not going into speciality training had grown and was a 'sizeable' part of the workforce.
Dr Prinsley said he believes priority should be given to UK graduates and physician associates – who have less training – could be used to fill some of the roles taken up by overseas recruits.
He said: 'The change that we need is not very difficult. We just need to make a situation in which we prioritise the UK training slots for the UK medical graduates. If we've got any slots we can't recruit to, then, of course, we extend it.'
He added: 'The problem has two solutions. We need less international medical graduates being recruited by the hospitals. We need to find an alternative way of staffing the rotas to run the hospitals.
'There's a sort of golden mean, which would allow us to sort out the ratios of international medical graduates to British graduates, and also provide a meaningful role for these graduates as physician associates.'
The British Medical Association will discuss the issue at its annual conference in Liverpool on Monday. In a motion put forward by members in the East Midlands, it asks the Government to 'significantly increase the number of training posts available for resident doctors'.
It echoes a similar call by the Royal College of Physicians, who wrote in February 'UK graduates must be supported and enabled to enter postgraduate training schemes to continue their training in the NHS'.
A Department of Health and Social Care spokesperson said: 'We are committed to building home-grown talent and ensuring UK medical graduates can find work in Britain – our 10 year health plan will tackle bottlenecks in the system.
'Internationally-trained staff remain an important part of the workforce but we should not be over reliant on overseas recruitment.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mass rollout of weight loss jabs begins on NHS
Mass rollout of weight loss jabs begins on NHS

Leader Live

time2 hours ago

  • Leader Live

Mass rollout of weight loss jabs begins on NHS

Around 220,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly through the NHS over the next three years. The drug is an antidiabetic drug which lowers blood sugar levels and and slows down how quickly food is digested. From Monday, GPs in England will be allowed to prescribe Mounjaro to severely obese people who also suffer from a range of other health problems. Patients previously needed to access the drugs through a special weight loss service. But leading family doctors said some GPs have expressed concern about the additional workload linked to the rollout. And pharmacy experts also said there could be pressure on supplies of the drug. In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. Dr Claire Fuller, from NHS England, said: 'This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today. 'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health – and greater access to weight loss drugs will make a significant difference to the lives of those people. 'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions. 'While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'While we recognise the potential benefits of weight loss drugs, we know many GPs are concerned about the implications of the rollout of weight loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments. 'The college shares these concerns, which is why we were pleased NHS England suggested a phased roll-out of Mounjaro as a treatment for weight loss. As and when this is escalated, appropriate resourcing for general practice – including access to 'wraparound' services – and training for GPs must follow. GLP-1s like #Ozempic, #Saxenda, #Wegovy, or #Mounjaro are not an easy #weightloss hack. Find out more about:🔵what they are ❓🔵how they're used 💊🔵who they help 💪 🔗Learn more: — EU Medicines Agency (@EMA_News) January 4, 2025 She added: 'GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely. 'More widely, whilst weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. 'We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.' Dr Hawthorne said there is no 'one size fits all approach' and that the rollout of the jabs should not 'come at the expense of other weight loss service'. She continued: 'The roll-out of weight loss medications in the NHS will need to be consistently evaluated to ensure that there is evidence that these prescriptions are of long-term benefit to patients.' Olivier Picard, chairman of the National Pharmacy Association, said: 'The demand for weight loss jabs continues to rise sharply, and more GPs have been directing patients back to pharmacies after initial inquiries, to access these treatments privately. 'As the NHS is now moving to implement National Institute for Health and Care Excellence (Nice) guidance, and tirzepatide becomes prescribable to more patients, we expect to see prescription volumes increase rapidly. 'However, NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately from a pharmacy. 'Pharmacists are experts in medication and many of us have lots of experience delivering weight loss injections as part of a package of care including lifestyle advice. 'We are well placed to help roll out weight loss treatment on the NHS, with the right funding to support it. 'The biggest concern we have is that prescribing these medications alone misses the point. 'They should be part of a comprehensive weight management strategy – combining lifestyle coaching, exercise, and nutritional guidance. In reality, many GPs lack the bandwidth to deliver the level of support needed to ensure proper understanding and follow-up. 'As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends – simply because the foundational lifestyle changes weren't addressed.' Around 29% of the adult population in the UK is obese. Health Secretary Wes Streeting said: 'Obesity is now one of the leading causes of ill health, costing the NHS billions. Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity. 'Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best', and this Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay. 'This rollout is an important step in making these medicines more widely available, and beginning to shift the focus of healthcare from sickness to prevention, which our forthcoming 10-year plan will deliver.'

Mounjaro weight loss jab: All you need to know
Mounjaro weight loss jab: All you need to know

Leader Live

time2 hours ago

  • Leader Live

Mounjaro weight loss jab: All you need to know

Some 220,000 people with the 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly, through the NHS over the next three years. Here the PA news agency takes a look at the drug and the rollout. – How does tirzepatide work? Tirzepatide, or Mounjaro, is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested. It makes you feel fuller for longer and therefore less hungry. If the jab is recommended by a healthcare professional, those using it will need to eat a balanced, reduced-calorie diet and to exercise regularly while taking it, according to the NHS website. – Who might be eligible for the drug? In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. It was previously only accessible to patients through a special weight loss service, to severely obese people who also suffer from a range of other health problems. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. – How would it be administered? The drug is usually delivered through a self-administered weekly injection which a doctor or nurse will show patients how to use, the NHS website says. – Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS. For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time. – What are the potential side effects? Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.

Mounjaro weight loss jab: All you need to know
Mounjaro weight loss jab: All you need to know

South Wales Guardian

time2 hours ago

  • South Wales Guardian

Mounjaro weight loss jab: All you need to know

Some 220,000 people with the 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly, through the NHS over the next three years. Here the PA news agency takes a look at the drug and the rollout. – How does tirzepatide work? Tirzepatide, or Mounjaro, is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested. It makes you feel fuller for longer and therefore less hungry. If the jab is recommended by a healthcare professional, those using it will need to eat a balanced, reduced-calorie diet and to exercise regularly while taking it, according to the NHS website. – Who might be eligible for the drug? In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. It was previously only accessible to patients through a special weight loss service, to severely obese people who also suffer from a range of other health problems. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. – How would it be administered? The drug is usually delivered through a self-administered weekly injection which a doctor or nurse will show patients how to use, the NHS website says. – Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS. For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time. – What are the potential side effects? Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store